We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Results for
"[search-keyword]"
Sponsor content
418 result(s) found, displaying 1 to 10
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OMJJARA momelotinib (as dihydrochloride monohydrate) 100 mg film-coated tablet bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OMJJARA momelotinib (as dihydrochloride monohydrate) 150 mg film-coated tablet bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OMJJARA momelotinib (as dihydrochloride monohydrate) 200 mg film-coated tablet bottle.
-
Cancellation by sponsorRequested by GlaxoSmithKline Australia Pty Ltd
-
Oct-2024Prescription medicine evaluationActive ingredient: Diphtheria toxoid, Pertactin, Pertussis filamentous haemagglutinin, Pertussis toxoid, Poliovirus, Tetanus toxoid.
-
Cancellation by sponsorRequested by GlaxoSmithKline Australia Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AREXVY Recombinant Respiratory Syncytial Virus pre-fusion F protein vaccine 120 micrograms powder vial and suspension vial suspension for injection.
-
Australian Public Assessment Report (AusPAR)Arexvy is a vaccine approved for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in individuals 60 years and older
-
May-2024Prescription medicine evaluationActive ingredient: momelotinib dihydrochloride monohydrate.
-
Cancellation by sponsorRequested by GlaxoSmithKline Australia Pty Ltd